Show Notes
Send us a voicemail! Medical device pharmacovigilance is complicated. Alongside clinical safety, there are technology risks, from cybersecurity threats to outdated software, that can leave patients vulnerable. In this two-part episode, Omar Aimer, president of ISoP and former co-lead of the Medical Device Safety Special Interest Group, discusses the challenges with medical device safety monitoring and what needs to change to keep patients safe. Tune in to find out: What defines a...
More from Drug Safety Matters
Send us a voicemail! Pharmacovigilance specialists can have very different roles depending on their organisation and job title. With so many career paths to choose from, how do you find your place? Myriam Salem from Health Canada and Francesco Salvo from the University of Bordeaux share advice on how to break into the field and navigate the job market. Tune in to find out: What PV work looks like across regulators, academia and industryWhich skills you need to remain competitiveHow to balance...
Send us a voicemail! Global pharmacovigilance requires harmonised methods, but solutions must be tailored to the local context. We sat down with Salvador Alvarado and Matthew Barwick from Uppsala Monitoring Centre to explore how local constraints affect drug safety and how a new film series by UMC can inspire PV professionals across borders. Tune in to find out: How the thalidomide tragedy triggered a global pharmacovigilance collaborationHow UMC supports members of the WHO Programme for Inte...
Send us a voicemail! Pharmacovigilance has traditionally focused on the patient at the receiving end of a medicine. But what happens to medicines once they leave the body? In this episode, Valentina Giunchi and Joe Mitchell unpack the emerging field of ecopharmacovigilance and explore how the One Health approach is reshaping the way we think about medicine safety across human, animal, and environmental systems. Tune in to find out: Where in the environment pharmaceutical residues are tu...
Send us a voicemail! For all its ease and speed, disproportionality analysis can be distorted by many biases, making it easy to misuse and misinterpret. Michele Fusaroli from Uppsala Monitoring Centre and Eugene van Puijenbroek from the Netherlands pharmacovigilance centre Lareb explain why we shouldn’t abuse this powerful but fragile tool. Tune in to find out: Why we should never treat disproportionality signals as verdictsHow poorly performed analyses affect scientists, regulators and patie...
Send us a voicemail! Medical device pharmacovigilance is complicated. Alongside clinical safety, there are technology risks, from cybersecurity threats to outdated software, that can put patients at risk. In this two-part episode, Omar Aimer, President of ISoP and former co-lead of the Medical Device Safety Special Interest Group, discusses the challenges with medical device safety monitoring and what needs to change to keep patients safe. Tune in to find out: How reporting for medical ...